Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

Overview of attention for article published in Lancet Oncology, January 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

news: 3 news outlets
twitter: 24 X users
patent: 2 patents

f1000: 1 research highlight platform
guideline: 1 clinical guideline source

Readers on

mendeley: 373 Mendeley

So far, Altmetric has seen 3 news stories from 3 outlets.

Toward Personalized Treatment Approaches in Soft Tissue Sarcomas

Cancer Network, 15 Jan 2024

Ciara Kelly, MBBCh, BAO Soft-tissue sarcomas (STS) are a rare, heterogeneous collection of tumors with more than 100…

ESMO 2020: Sarcomas and GISTs roundup - ecancer

ecancer, 09 Oct 2020

by Arifi Samia, Hassan II University Hospital, Faculty of Medicine and Pharmacy, Sidi Mohamed Ben Abdellah University, Fez…

Nivolumab With or Without Ipilimumab in Advanced Sarcoma

The ASCO Post, 18 Sep 2018

By Matthew Stenger Posted: 2/5/2018 10:50:49 AM Last Updated: 9/17/2018 3:32:34 PM Advertisement Nivolumab plus ipilimumab…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.